Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LADR Protocol for HCV in Liver Transplant Candidates
NCT00135798Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Sep 2005
- Primary completion
- Dec 2009
- Modality
- Polymer-based Nanoparticles, Orthosteric Ligands, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of peginterferon alfa-2b and ribavirin in hepatitis C (HCV) (3 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Patients Who Are Negative for Hepatitis C Virus (HCV) RNA at 3 Months Post-transplant. Started Sep 2005; status: completed.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00135798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135798.